Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies

ABSTRACT With the emerging popularity of immune‐modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single‐system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic lateral sclerosis (ALS), the use of these therapies to treat patients has been largely unsuccessful and likely premature given our lack of understanding of how the immune system influences disease progression and initiation. In addition, we still have an incomplete understanding of the role of these responses in our model systems and how this may translate clinically to human patients. In this review we discuss preclinical evidence and clinical trial results for a selection of recently conducted studies in ALS. We provide evidence‐based reasoning for the failure of these trials and offer suggestions to improve the design of future investigations. Muscle Nerve 59:23–33, 2019 See invited review on pages 10–22 in this issue.